Filing Details
- Accession Number:
- 0001567619-22-021361
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-12-06 21:09:42
- Reporting Period:
- 2022-11-02
- Accepted Time:
- 2022-12-06 21:09:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1048477 | Biomarin Pharmaceutical Inc | BMRN | Pharmaceutical Preparations (2834) | 680397820 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1221590 | Jacques Jean Bienaime | C/O Biomarin Pharmaceutical Inc. 770 Lindaro St. San Rafael CA 94901 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-11-02 | 100 | $86.12 | 322,924 | No | 4 | L | Direct | |
| Common Stock | Disposition | 2022-12-02 | 471 | $103.97 | 322,453 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-12-02 | 600 | $103.97 | 321,853 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-12-02 | 260 | $103.98 | 321,593 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-12-02 | 100 | $104.00 | 321,493 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-12-02 | 69 | $104.06 | 321,424 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | L | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 247,533 | Indirect | Shares held by Jean-Jacques Bienaime Family Trust |
Footnotes
- The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $86.1178 on November 2, 2022. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
Billionaire Hedge Funds
